Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer

treatment if they come back after chemotherapy. Treatment with two drugs combined may be able to help. Objective To compare M6620 plus topotecan to topotecan alone in

topotecan
  • 1 views
  • 18 Nov, 2019
  • 1 location
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have

monoclonal antibodies
cancer
metastasis
neutrophil count
tumor cells
  • 0 views
  • 24 Nov, 2021
  • 1 location
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic

neutrophil count
berzosertib
absolute neutrophil count
adjuvant therapy
metastasis
  • 31 views
  • 17 Jun, 2022
  • 7 locations
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung cancer that has spared to other placed in the body (advanced). Berzosertib may stop …

neutrophil count
cardiotoxic agents
hcv viral load
gemcitabine
systemic chemotherapy
  • 0 views
  • 28 Jun, 2022
  • 17 locations
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

kill tumor cells and shrink tumors. Giving M6620 and radiation therapy may kill tumor cells more effectively than radiation alone or shrink or stabilize breast cancer for longer than radiation therapy

serum pregnancy test
breast surgery
carcinoma in situ
antineoplastic
neutrophil count
  • 0 views
  • 13 Jun, 2022
  • 5 locations
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth …

  • 0 views
  • 16 Jun, 2022
  • 14 locations